NCI Definition: A rare tumor containing unequivocal elements of both hepatocellular and cholangiocarcinoma that are intimately admixed. This tumor should be distinguished from separate hepatocellular carcinoma and cholangiocarcinoma arising in the same liver. The prognosis of this tumor is poor. [1]

Combined hepatocellular carcinoma and cholangiocarcinomas most frequently harbor alterations in TP53, PBRM1, CDKN2B, CDKN2A, and BAP1 [2].

Most Commonly Altered Genes in Combined Hepatocellular Carcinoma and Cholangiocarcinoma

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, CDKN2B Loss, and CDKN2A Loss are the most common alterations in combined hepatocellular carcinoma and cholangiocarcinoma [2].

Top Alterations in Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Disease Details

Hepatocholangiocarcinoma, Carcinoma of Liver and Intrahepatic Biliary Tract, Mixed Hepatocellular Cholangiocarcinoma, Cholangiohepatoma, Combined Hepatocellular Cancer and Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Liver mixed hepatocellular cholangiocarcinoma, Liver and Intrahepatic Biliary Tract Carcinoma, Carcinoma of the Liver and Intrahepatic Biliary Tract
Liver and Intrahepatic Bile Duct Carcinoma
OncoTree Name
Hepatocellular Carcinoma plus Intrahepatic Cholangiocarcinoma
OncoTree Code


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.